PL374310A1 - Zastosowanie pramipexsolu do leczenia stwardnienia zanikowego bocznego - Google Patents

Zastosowanie pramipexsolu do leczenia stwardnienia zanikowego bocznego

Info

Publication number
PL374310A1
PL374310A1 PL02374310A PL37431002A PL374310A1 PL 374310 A1 PL374310 A1 PL 374310A1 PL 02374310 A PL02374310 A PL 02374310A PL 37431002 A PL37431002 A PL 37431002A PL 374310 A1 PL374310 A1 PL 374310A1
Authority
PL
Poland
Prior art keywords
pramipexole
lateral sclerosis
amyotrophic lateral
treat amyotrophic
als
Prior art date
Application number
PL02374310A
Other languages
English (en)
Inventor
James P.Jr. Bennett
Original Assignee
University Of Virginia Patent Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Virginia Patent Foundation filed Critical University Of Virginia Patent Foundation
Publication of PL374310A1 publication Critical patent/PL374310A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Artificial Filaments (AREA)
  • Noodles (AREA)
PL02374310A 2001-12-11 2002-12-02 Zastosowanie pramipexsolu do leczenia stwardnienia zanikowego bocznego PL374310A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33938301P 2001-12-11 2001-12-11
US34737102P 2002-01-11 2002-01-11

Publications (1)

Publication Number Publication Date
PL374310A1 true PL374310A1 (pl) 2005-10-03

Family

ID=26991607

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02374310A PL374310A1 (pl) 2001-12-11 2002-12-02 Zastosowanie pramipexsolu do leczenia stwardnienia zanikowego bocznego

Country Status (19)

Country Link
US (4) US7157480B2 (pl)
EP (4) EP2305252A1 (pl)
JP (2) JP4500543B2 (pl)
KR (1) KR20040066890A (pl)
CN (1) CN1617720A (pl)
AT (1) ATE480235T1 (pl)
AU (1) AU2002360600B2 (pl)
CA (1) CA2468747C (pl)
CY (1) CY1111237T1 (pl)
DE (1) DE60237635D1 (pl)
DK (1) DK1453505T3 (pl)
ES (2) ES2432527T3 (pl)
HU (1) HUP0500001A3 (pl)
IL (1) IL162408A0 (pl)
MX (1) MXPA04005572A (pl)
PL (1) PL374310A1 (pl)
PT (1) PT1453505E (pl)
RU (1) RU2004121177A (pl)
WO (1) WO2003049705A2 (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040066890A (ko) * 2001-12-11 2004-07-27 유니버시티 오브 버지니아 페이턴트 파운데이션 근위축성 측삭 경화증 치료를 위한 프라미펙솔의 용도
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
ATE444750T1 (de) * 2005-08-15 2009-10-15 Univ Virginia Neurorestauration mit r(+) pramipexol
CA2626249A1 (en) * 2005-10-18 2007-04-26 Boehringer Ingelheim International Gmbh Use of pramipexol for treating moderate to severe restless legs syndrome (rls)
US8518926B2 (en) * 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
US20070259930A1 (en) * 2006-04-10 2007-11-08 Knopp Neurosciences, Inc. Compositions and methods of using r(+) pramipexole
CN102160865A (zh) 2006-05-16 2011-08-24 诺普神经科学股份有限公司 R(+)和s(-)普拉克索的组合物以及使用该组合物的方法
EP2465500A1 (en) * 2006-05-16 2012-06-20 Knopp Neurosciences, Inc. Therapeutically effective amounts of R(+) and S(-) pramipexole for use in the treatment of parkinson's disease
AU2013209376B2 (en) * 2006-12-14 2016-05-05 Knopp Biosciences Llc Compositions and methods of using (r)-pramipexole
AU2016210640B2 (en) * 2006-12-14 2018-02-22 Knopp Biosciences Llc Compositions and methods of using (r)-pramipexole
US8524695B2 (en) 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
WO2008074033A1 (en) * 2006-12-14 2008-06-19 Knopp Neurosciences, Inc. Compositions and methods of using (r)-pramipexole
US8519148B2 (en) 2007-03-14 2013-08-27 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazole diamines
CN101677564A (zh) * 2007-03-14 2010-03-24 诺普神经科学股份有限公司 (6r)-4,5,6,7-四氢-n6-丙基-2,6-苯并噻唑-二胺的改良释放制剂及其使用方法
GB0811642D0 (en) * 2008-06-25 2008-07-30 Univ Edinburgh Assay
JP2012500283A (ja) * 2008-08-19 2012-01-05 ノップ ニューロサイエンシーズ、インク． （ｒ）−プラミペキソールを使用した組成物並びにその方法
AU2010262970A1 (en) * 2009-06-19 2012-01-12 Knopp Neurosciences, Inc. Compositions and methods for treating amyotrophic lateral sclerosis
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
WO2014031883A1 (en) * 2012-08-23 2014-02-27 Susan Marie Metcalfe Neurotherapeutic nanoparticle compositions and devices
US10125127B2 (en) 2012-11-29 2018-11-13 Wayne State University Neuroprotective agents for treatment of neurodegenerative diseases
US10874669B2 (en) 2012-11-29 2020-12-29 Wayne State University Neuroprotective agents for treatment of neurodegenerative diseases
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
RS67279B1 (sr) 2013-07-12 2025-10-31 Areteia Therapeutics Inc Lečenje povišenih nivoa eozinofila i/ili bazofila
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
EP3033081B1 (en) 2013-08-13 2021-05-12 Knopp Biosciences LLC Compositions and methods for treating chronic urticaria
ES2813674T3 (es) 2013-08-13 2021-03-24 Knopp Biosciences Llc Composiciones y métodos para el tratamiento de trastornos de células plasmáticas y trastornos prolinfocíticos de células b
CN111278425B (zh) 2017-09-11 2024-06-11 耶路撒冷希伯来大学伊萨姆研究开发有限公司 用于向脑部经鼻给药药物和用于全身作用的组合物和方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US560420A (en) 1896-05-19 Steam and oil separator
DE3572485D1 (en) 1984-12-22 1989-09-28 Thomae Gmbh Dr K Tetrahydro-benzothiazoles, their production and their use as intermediates or drugs
DE3447075A1 (de) * 1984-12-22 1986-07-03 Dr. Karl Thomae Gmbh, 7950 Biberach Tetrahydro-benzthiazole, deren herstellung und deren verwendung als zwischenprodukte oder als arzneimittel
DE3937271A1 (de) 1989-11-09 1991-05-16 Boehringer Ingelheim Kg Transdermale applikation von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol
FR2688138B1 (fr) * 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.
US6156777A (en) * 1994-12-15 2000-12-05 Pharmacia & Upjohn Company Use of pramipexole as a neuroprotective agent
US5650420A (en) * 1994-12-15 1997-07-22 Pharmacia & Upjohn Company Pramipexole as a neuroprotective agent
ES2159362T3 (es) * 1995-10-26 2001-10-01 Sanofi Synthelabo Utilizacion de la 1-(2-naft-2-iletil)-4-(3-trifluorometilfenil)-1,2,3,6-tetrahidropiridina para la preparacion de medicamentos destinados para el tratamiento de la esclerosis lateral amiotrofica.
GB9705428D0 (en) * 1997-03-15 1997-04-30 Knoll Ag Therapeutic agents
US6197339B1 (en) * 1997-09-30 2001-03-06 Pharmacia & Upjohn Company Sustained release tablet formulation to treat Parkinson's disease
PE20000728A1 (es) * 1998-06-26 2000-08-21 Cocensys Inc Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda
DE19830201A1 (de) * 1998-07-07 2000-01-13 Boehringer Ingelheim Pharma Mittel mit antidepressiver Wirkung
CA2301899C (en) * 1998-07-27 2008-11-18 Boehringer Ingelheim Pharma Kg Agent with an antidepressant activity
IL142896A0 (en) * 1998-11-02 2002-04-21 Elan Corp Plc Multiparticulate modified release composition
DE19938825A1 (de) 1999-08-19 2001-04-26 Boehringer Ingelheim Pharma Wirkstoffkombination mit Clonidin
WO2001022820A1 (en) 1999-09-30 2001-04-05 The General Hospital Corporation Use of pramipexole as a treatment for cocaine craving
PE20011074A1 (es) 2000-02-23 2001-10-04 Upjohn Co Uso de pramipexol en el tratamiento de trastornos de adiccion
CA2415815A1 (en) * 2000-07-06 2002-01-17 Nigel H. Greig Tetrahydrobenzothiazole analogues as neuroprotective agents
DE10037619A1 (de) * 2000-08-02 2002-02-14 Daimler Chrysler Ag Anordnung von Bedienelementen
ES2187249B1 (es) * 2000-09-18 2004-09-16 Synthon Bv Procedimiento para la preparacion de 2-amino-6-(alquil)amino-4,5,6,7-tetrahidrobenzotiazoles.
US20020151526A1 (en) * 2000-10-06 2002-10-17 Gallop Mark A. Bile-acid prodrugs of L-dopa and their use in the sustained treatment of parkinsonism
DE10137082A1 (de) * 2001-07-28 2003-02-13 Hexal Ag Matrixkontrolliertes transdermales therapeutisches System zur Anwendung von Pramiprexol und Ropinirol
KR20040066890A (ko) * 2001-12-11 2004-07-27 유니버시티 오브 버지니아 페이턴트 파운데이션 근위축성 측삭 경화증 치료를 위한 프라미펙솔의 용도
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
US6927036B2 (en) * 2002-02-19 2005-08-09 Xero Port, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
US20050226926A1 (en) * 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
SI1610791T1 (sl) * 2003-03-31 2011-05-31 Titan Pharmaceuticals Inc Implantibilna polimerna naprava za zadržano sproščanje dopaminskega agonista
WO2005010011A2 (en) * 2003-07-15 2005-02-03 Xenoport, Inc. Methods of synthesis of acyloxyalkyl compounds
UA88477C2 (ru) * 2004-08-13 2009-10-26 Бёрингер Ингельхайм Интернациональ Гмбх Композиция пеллеты пролонгированного высвобождения, которая содержит прамипексол или его фармацевтически приемлемую соль, способ ее изготовления и ее применение
TW200616604A (en) * 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
ATE444750T1 (de) * 2005-08-15 2009-10-15 Univ Virginia Neurorestauration mit r(+) pramipexol

Also Published As

Publication number Publication date
WO2003049705A2 (en) 2003-06-19
WO2003049705A3 (en) 2004-01-29
EP2305253A1 (en) 2011-04-06
JP2005516911A (ja) 2005-06-09
EP1453505A4 (en) 2007-01-10
RU2004121177A (ru) 2005-03-10
AU2002360600A1 (en) 2003-06-23
EP2246053A1 (en) 2010-11-03
JP2010031059A (ja) 2010-02-12
EP2305252A1 (en) 2011-04-06
KR20040066890A (ko) 2004-07-27
DE60237635D1 (de) 2010-10-21
DK1453505T3 (da) 2010-11-15
ATE480235T1 (de) 2010-09-15
US20070105918A1 (en) 2007-05-10
US20110301210A1 (en) 2011-12-08
MXPA04005572A (es) 2004-12-06
EP2246053B1 (en) 2013-09-18
CA2468747A1 (en) 2003-06-19
ES2351303T3 (es) 2011-02-02
CA2468747C (en) 2011-05-31
PT1453505E (pt) 2010-12-16
EP1453505A2 (en) 2004-09-08
JP4500543B2 (ja) 2010-07-14
AU2002360600B2 (en) 2007-11-29
ES2432527T3 (es) 2013-12-04
HUP0500001A2 (hu) 2005-04-28
HK1150153A1 (en) 2011-11-04
IL162408A0 (en) 2005-11-20
CY1111237T1 (el) 2015-06-11
CN1617720A (zh) 2005-05-18
US20050032856A1 (en) 2005-02-10
HUP0500001A3 (en) 2005-11-28
US7157480B2 (en) 2007-01-02
US20130172394A1 (en) 2013-07-04
EP1453505B1 (en) 2010-09-08

Similar Documents

Publication Publication Date Title
IL162408A0 (en) Use of pramipexole to treat amyotrophic lateral scelrosis
GB0108592D0 (en) Therapeutic agents
AU2001252958A1 (en) Compounds and methods to treat alzheimer's disease
IL132797A0 (en) Compounds and methods for the inhibition of the expression of vcam-1
WO2002002505A3 (en) Compounds to treat alzheimer's disease
MXPA03008135A (es) Combinacion de analogos de epotilona y agentes quimioterapeuticos para tratamiento de enfermedades proliferativas.
MXPA04003796A (es) Tioacetamidas sustituidas.
DE69629290D1 (en) Substituierte sulfonylphenylheterocyclen als cyclooxygenase-2 und lipoxygenase inhibitoren
GB0117326D0 (en) Napthoquinone-type inhibitors of protein aggregation
SI1465626T1 (sl) Farmacevtski sestavki (komplet), ki obsegajo dihidropiridionske spojine in imunoregulacijsko (ali protivnetno) sredstvo, in njihove uporabe
DE60210093D1 (de) Beta-amino-tetrahydroimidazo(1,2-a)pyrazine und -tetrahydrotriazolo(4,3-a)pyrazine als dipeptidyl peptidase inhibitoren zur behandlung oder prevention von diabetes
WO2002002520A3 (en) Compounds to treat alzheimer's disease
MXPA02011288A (es) Tioacetamidas substituidas.
PL343373A1 (en) Treatment of parasitic diseases by inhibition of cysteine proteases of the papain superfamily
MA27929A1 (fr) Utilisation de calcitonine pour le traitement de l'osteoarthrite
MY139368A (en) Novel cyclohexyl sulphones
MXPA03001643A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
AP1896A (en) The method of treating cancer
WO2002046225A3 (en) Use of sarp-1 for the treatment and/or prevention of scleroderma
WO2003055440A8 (en) Compositions and methods for the treatement of immune related diseases
AU1278600A (en) Novel therapeutic application of nicergoline
WO2003059387A3 (en) Combination comprising anti-cd52 antibodies and other therapeutic agents for treatment for multiple sclerosis
SI1276495T1 (sl) Uporaba rekombinantnega pljucnega surfaktanta za zgodnje zdravljenje akutnih pljucnih bolezni
MXPA03001644A (es) Composiciones y metodos para el diagnostico y tratamiento de tumor.
AU1278700A (en) Novel therapeutic use of 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergoline

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)